LIMITATIONS
myocardial ischemia
MYOCARDIAL ISCHEMIA
There are a number of limitations with regard to the SCRAP trial. One limitation is the difference in myocardial ischemia on which the sample size calculation is based. The power of the study is based on a relative reduction in myocardial ischemia of 25% after treatment with SCS, in absolute numbers a reduction from 10% to 7.5% of myocardial ischemia. Whilst this is a relatively modest difference, it is deemed clinically relevant. Patients with more than 10% myocardial ischemia have a worse prognosis in comparison to patients with less than 10% myocardial ischemia,